CIA
REGN icon

Cascade Investment Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Cascade Investment Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,275
Closed -$1.63M – 115
2023
Q2 		$1.63M Buy
2,275
+16
+0.7% +$12.3K 1.22% 22
2023
Q1 		$1.86M Sell
2,259
-45
-2% -$33.9K 1.47% 8
2022
Q4 		$1.66M Sell
2,304
-87
-4% -$64.2K 1.38% 13
2022
Q3 		$1.79M Sell
2,391
-441
-16% -$278K 1.54% 8
2022
Q2 		$1.67M Buy
2,832
+5
+0.2% +$3.25K 1.32% 11
2022
Q1 		$1.97M Hold
2,827
– – 1.2% 15
2021
Q4 		$1.79M Buy
2,827
+781
+38% +$480K 1.05% 28
2021
Q3 		$1.24M Hold
2,046
– – 0.81% 62
2021
Q2 		$1.14M Buy
+2,046
New +$1.04M 0.72% 78

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Cascade Investment Advisors's REGN Position: Q3 2023 in Review

Cascade Investment Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q3 2023, closing a stake of 2,275 shares — an estimated $1.63M sold.

Cascade Investment Advisors first reported a position in REGN in Q2 2021 and held it in 9 quarters. The position peaked at $1.97M in Q1 2022. 1,177 funds tracked by Wall St. Rank hold REGN as of Q3 2023.

  • Cascade Investment Advisors reported no remaining Regeneron Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Cascade Investment Advisors sold 2,275 Regeneron Pharmaceuticals shares in Q3 2023, an estimated $1.63M.
  • Cascade Investment Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2021 and held it in 9 quarters.
  • Cascade Investment Advisors's Regeneron Pharmaceuticals position peaked at $1.97M in Q1 2022.
  • 1,177 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2023.

Based on Cascade Investment Advisors's 13F filing for Q3 2023, filed 30 Oct 2023.